2013-01-28T16:11:36-06:00 2012-06-30 232932984 PARENTEBEARD LLC 1650 MARKET STREET SUITE 4500 PHILADELPHIA PA 19103 990 2011-07-01 210672684 CORIELL INSTITUTE FOR MEDICAL RESEARCH CORI 8567574824 403 HADDON AVENUE CAMDEN NJ 08103 JOSEPH L MINTZER 8567574824 2013-01-28 1 JULIUS GREEN CPA P00350393 2159720701 2011 2016-03-07 17:11:31Z JOSEPH L MINTZER 403 HADDON AVENUE CAMDEN NJ 08103 20852855 0 X WWW.CORIELL.ORG X 1953 NJ BIOMEDICAL RESEARCH ORGANIZATION DEDICATED TO UNDERSTANDING HUMAN GENETIC DISEASES. 24 22 126 0 0 0 1966871 3377510 16311147 17023011 212767 212154 34173 -24121 18524958 20588554 0 0 0 0 8861962 9024321 0 0 2205 9052128 10328843 17914090 19353164 610868 1235390 38732678 38999719 12611249 12108198 26121429 26891521 X THE CORIELL INSTITUTE FOR MEDICAL RESEARCH SEEKS TO DISCOVER THE CAUSES OF CANCER AND OTHER GENETIC DISEASES IN ORDER TO IMPROVE THE HEALTH OF HUMANKIND, THROUGH SCIENTIFIC RESEARCH, BANKING OF CELL AND TISSUES, AND EDUCATION. AT THE CORIELL INSTITUTE, OUR MISSION IS TO SUPPORT THE GIFT OF GOOD HEALTH. 0 0 15295444 0 17023011 CORIELL INSTITUTE FOR MEDICAL RESEARCH, FOUNDED IN 1953 AND BASED IN CAMDEN, NEW JERSEY, IS AN INDEPENDENT NON-PROFIT RESEARCH INSTITUTE DEDICATED TO THE STUDY OF THE HUMAN GENOME. EXPERT STAFF AND PIONEERING PROGRAMS IN THE FIELDS OF PERSONALIZED MEDICINE, CELL BIOLOGY, CYTOGENETICS, GENOTYPING, AND BIOBANKING DRIVE OUR MISSION. IT MAINTAINS REPOSITORIES FOR CELL LINES AND DNA AND DISTRIBUTES OVER 20,000 BIOMATERIALS ANNUALLY TO RESEARCHERS NATIONALLY AND INTERNATIONALLY.THE CORIELL PERSONALIZED MEDICINE COLLABORATIVE (CPMC) RESEARCH STUDY IS SEEKING TO UNDERSTAND THE USEFULNESS OF GENETIC RISK AND PHARMACOGENOMICS IN CLINICAL DECISION-MAKING AND HEALTHCARE MANAGEMENT.CORIELL HAS A DISTINGUISHED HISTORY IN CELL BIOLOGY, PURSUING CURRENTLY INDUCED PLURIPOTENT STEM (IPS) CELL RESEARCH. THESE POWERFUL CELLS ARE REVOLUTIONIZING THE WAY HUMAN DISEASE IS STUDIED AND HOW DRUGS ARE DEVELOPED. CORIELL OFFERS CUSTOM RESEARCH SERVICES INCLUDING CELL CULTURE, CYTOGENETIC ANALYSES, AND MOLECULAR BIOLOGY. ITS CLIA-CERTIFIED GENOTYPING AND MICROARRAY CENTER OFFERS HIGH-THROUGHPUT DNA ANALYSIS SYSTEMS USING THE PLATFORMS OF TWO LEADING PROVIDERS.ESSENTIAL TO THE INSTITUTE'S SUPPORT OF INTERNATIONAL SCIENTIFIC RESEARCH IS THE CORIELL BIOBANK. FROM THIS RENOWNED CELL BANK, CORIELL MANAGES AND DISTRIBUTES THE WORLD'S MOST DIVERSE COLLECTION OF CELL LINES, DNA, AND OTHER BIOLOGICAL RESOURCES. THE CORIELL BIOBANK PROVIDED SUPPORT TO THE HUMAN GENOME PROJECT, A WORLDWIDE PROGRAM TO MAP THE ENTIRE HUMAN GENOME, AND TO THE INTERNATIONAL HAPMAP PROJECT, A PROJECT PROVIDING AN EFFICIENT TOOL TO IDENTIFY DISEASE-CAUSING GENES.CORIELL'S BIOBANKING OPERATION IS FUNDED BY SEVERAL NATIONAL INSTITUTES OF HEALTH AWARDS. 15295444 1 1 0 1 0 0 0 0 0 1 1 0 0 1 1 1 0 1 0 0 1 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 45 0 1 126 1 0 0 0 0 0 0 0 0 0 0 X 24 22 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NJ PA NY X JOSEPH L MINTZER EXECUTIVE VPCOO 8567574824 403 HADDON AVENUE CAMDEN NJ 08103 MICHAEL F CHRISTMAN PHD 40.00 X X 447619 0 21783 JOHN AFFLECK 1.00 X 0 0 0 PETER DRISCOLL 1.00 X 0 0 0 JOANNE FREDERICKS 1.00 X 0 0 0 DAVID FRIEDMAN 1.00 X X 0 0 0 LIESL HENDERSON 1.00 X 0 0 0 ROBERT KIEP 1.00 X X 0 0 0 CALVIN KNOWLTON 1.00 X 0 0 0 STEPHEN KOPLIN 1.00 X 0 0 0 CHARLES LORD 1.00 X 0 0 0 CONSTANCE MADARA 1.00 X 0 0 0 MARC MASER 1.00 X X 0 0 0 JOSEPH PARRILLO 1.00 X 0 0 0 MICHAEL SANYOUR 1.00 X 0 0 0 NEWBOLD STRONG 1.00 X 0 0 0 EDWARD VINER 1.00 X 0 0 0 ERYNN GORDON 40.00 X X 107622 0 16122 JERRY JOHNSON 1.00 X 0 0 0 NICHOLAS KOVICH 1.00 X 0 0 0 BRADLEY KING 1.00 X 0 0 0 WADIA MULLA 1.00 X 0 0 0 FRANK GIORDANO 1.00 X 0 0 0 BRIAN LITTEN 1.00 X 0 0 0 ARNAUD BASTIEN 1.00 X 0 0 0 JOSEPH L MINTZER 40.00 X 268901 0 31011 PATRICIA L WHITMAN 40.00 X 189285 0 14251 JOAN MCMANUS 40.00 X 41743 0 4813 NORMAN P GERRY PHD 40.00 X 126653 0 13849 STEVEN J MADORE PHD 40.00 X 132765 0 23555 SCOTT E MEGILL 40.00 X 208758 0 28758 COURTNEY KRONENTHAL 40.00 X 125087 0 18825 MARK BELLAFANTE 40.00 X 118983 0 22686 1767416 0 195653 9 0 1 0 0 15135 70025 1037000 2255350 3377510 GOVT FEES & CONTRACTS 621500 13058499 13058499 NON-GOVERNMENT REPOSIT 621500 3840790 3840790 INVESTIGATOR DIRECTED 621500 123722 123722 17023011 208218 208218 10000 5000 5000 5000 5000 197585 193649 3936 3936 3936 18660 70025 65652 -46992 -46992 SCIENCE FAIR 900099 17750 17750 MISCELLANEOUS INCOME 900099 121 121 17871 20588554 17023011 0 188033 963218 963218 6287736 5379214 908522 247545 214504 33041 1041173 811599 229574 484649 387212 97437 28886 28886 118867 8091 110776 45050 45050 778726 720181 58545 4899912 4609189 290723 599410 463186 134019 2205 224388 140326 84062 208486 208486 2165139 1581713 583426 271674 198468 73206 MAINTENANCE 842777 685430 157347 OPERATING EXPENSES 133138 96331 36807 MEMBERSHIPS 12390 12390 19353164 15295444 4055515 2205 1200 1200 1460988 1768884 2492109 3918722 1215734 1009642 242749 215241 193486 252140 323177 382248 29161941 16842417 13493927 12319524 5101595 4911350 500000 500000 13707713 13720768 38732678 38999719 945606 1093021 5412663 4688561 5208599 5083909 1044381 1242707 12611249 12108198 X 11548367 12249505 13756484 13825438 816578 816578 26121429 26891521 38732678 38999719 X 1235390 -465298 X X 0 1 1 X 1 1 X 3891023 2169754 1696487 3652779 3330518 14740561 3891023 2169754 1696487 3652779 3330518 14740561 2351608 12388953 480295 439599 176017 100684 218218 1414813 1312 37321 49657 18090 17871 124251 16279625 73691402 0.76100 0.74780 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 45050 45050 19308114 19353164 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 111078 48000 38750 45050 242878 250000 250000 250000 250000 1000000 1500000 5601595 10189 -200434 0 0 5411350 6915104 239008 998335 2549198 1654 5601595 8686542 878716 2618000 32154 6915104 16274149 93670 -3825261 3856016 8686542 0.30000 0.15000 0.55000 0 0 245000 245000 11758472 4625842 7132630 1856050 1435225 420825 15227784 10781350 4446434 74635 74635 12319524 SUPPLEMENTAL RETIREMENT ACCOUNTS 137884 NEW JERSEY CORD BLOOD BANK 4705000 USE OF RESEARCH FACILITY 7058270 SPLIT-INTEREST AGREEMENTS 953111 OTHER MISCELLANEOUS ASSETS 8515 DEFERRED FINANCING COSTS, NET 112988 UNDER RECOVERY OF IDC 745000 13720768 ADVANCES ON HAND 792310 ANNUITY PAYMENT LIABILITY - CHARITABLE GIFT ANNUITIES 31886 DERIVATIVE FINANCIAL INSTRUMENT 418511 1242707 20588554 19353164 1235390 -396348 -68950 -465298 770092 20846183 -396348 652275 -68950 186977 20659206 -70652 -70652 20588554 20076091 652275 70652 722927 19353164 0 19353164 DESCRIPTION OF INTENDED USE OF ENDOWMENT FUNDS: PART V, LINE 4: THE INSTITUTE'S ENDOWMENT FUNDS ARE USED TO SUPPORT THE SHORT AND LONG TERM GOALS OF THE INSTITUTE. THE INSTITUTE USED A 4% SPENDING RATE IN FISCAL 2012 TO DETERMINE THE AMOUNT OF ENDOWMENT EARNINGS TO BE ALLOCATED TO OPERATIONS FROM INTERNALLY MANAGED ENDOWMENTS. THE SPENDING RATE, WHICH IS SUBJECT TO REVIEW BY THE INSTITUTE'S BOARD OF TRUSTEES, IS APPLIED TO A MOVING AVERAGE OF ANNUAL ENDOWMENT LEVELS OVER THE PRIOR THREE YEARS. AT ITS DISCRETION THE BOARD MAY APPROVE DRAWS OF ADDITIONAL FUNDS ABOVE THE SPENDING RATE TO SUPPORT SPECIFIC GOALS OF THE INSTITUTE. DESCRIPTION OF UNCERTAIN TAX POSITIONS UNDER FIN 48: PART X: THE INSTITUTE ACCOUNTS FOR UNCERTAINTY IN INCOME TAXES USING A RECOGNITION THRESHOLD OF MORE-LIKELY-THAN NOT TO BE SUSTAINED UPON EXAMINATION BY THE APPROPRIATE TAXING AUTHORITY. MEASUREMENT OF THE TAX UNCERTAINTY OCCURS IF THE RECOGNITION THRESHOLD HAS BEEN MET. MANAGEMENT DETERMINED THAT THERE WERE NO TAX UNCERTAINTIES THAT MET THE RECOGNITION THRESHOLD IN 2012 AND 2011. THE INSTITUTE'S FEDERAL EXEMPT ORGANIZATION BUSINESS INCOME TAX RETURNS FOR YEARS ENDED JUNE 30, 2011, 2010 AND 2009 REMAIN SUBJECT TO EXAMINATION BY THE INTERNAL REVENUE SERVICE. PART XI, LINE 8 - OTHER ADJUSTMENTS: CHANGE IN VALUE OF SPLIT-INTEREST AGREEMENTS 25,079. CHANGE IN VALUE OF FUTURE BUILDING OCCUPANCY -64,636. CHANGE IN FAIR VALUE OF DERIVATIVE FINANCIAL INSTRUMENT -29,393. TOTAL TO SCHEDULE D, PART XI, LINE 8: -68,950. PART XII, LINE 2D - OTHER ADJUSTMENTS: CHANGE IN VALUE OF SPLIT-INTEREST AGREEMENTS 25,079. CHANGE IN VALUE OF FUTURE BUILDING OCCUPANCY -64,636. CHANGE IN VALUE OF DERIVATIVE FINANCIAL INSTRUMENT -29,393. PART XII, LINE 4B - OTHER ADJUSTMENTS: RENTAL EXPENSES -5,000. FUNDRAISING EXPENSES -65,652. PART XIII, LINE 2D - OTHER ADJUSTMENTS: RENTAL EXPENSES 5,000. FUNDRAISING EXPENSES 65,652. EUROPE 0 0 LICENSING TECHNOLOGY THERE IS NO ACTIVITY IN FOREIGN REGIONS. THE ORGANIZATION RECEIVES ROYALTIES FOR SHARED MEDICAL TECHNOLOGY WITH AN ITALIAN BIO-TECH FIRM. 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 SCHEDULE F, PART I, LINE 3: THE ORGANIZATION RECEIVES ROYALTY PAYMENTS FROM AN ITALIAN BUSINESS ENTITY FOR SOFTWARE LICENSING. THE ORGANIZATION DOES NOT HAVE ANY OFFICES OR EMPLOYEES IN A FOREIGN LOCATION. THE ORGANIZATION ALSO DOES NOT INCUR ANY EXPENDITURES RELATED TO FOREIGN ACTIVITIES. WHAT'S IN YOUR GENES 88685 70025 18660 5161 38243 3000 19248 88685 70025 18660 5161 38243 3000 19248 65652 -46992 X X X X X X 1 1 0 0 0 0 0 1 0 MICHAEL F CHRISTMAN PHD 417619 0 30000 0 0 0 17150 0 4633 0 469402 0 0 0 JOSEPH L MINTZER 251401 0 17500 0 0 0 17150 0 13861 0 299912 0 0 0 PATRICIA L WHITMAN 132381 0 0 0 56904 0 9431 0 4820 0 203536 0 0 0 STEVEN J MADORE PHD 132765 0 0 0 0 0 9694 0 13861 0 156320 0 0 0 SCOTT E MEGILL 188758 0 20000 0 0 0 14897 0 13861 0 237516 0 0 0 PART I, LINES 4A-B PATRICIA WHITMAN, THE FORMER DIRECTOR OF FINANCE, WAS TERMINATED IN DECEMBER 2011. SHE RECEIVED $59,904.25 IN SEVERANCE PAY. JOSEPH MINTZER PARTICIPATES IN A NON-QUALIFIED DEFERRED COMPENSATION PLAN. THE COMPENSATION COMMITEE DETERMINES, ON AN ANNUAL BASIS, WHETHER TO MAKE A CONTRIBUTION AND THE AMOUNT. THERE WERE NO CONTRIBUTIONS MADE TO THE PLAN DURING THE CURRENT REPORTING PERIOD. PART I, LINE 7 THE COMPENSATION COMMITTEE DETERMINED THAT MICHAEL CHRISTMAN, JOSEPH MINTZER, AND SCOTT MEGILL WERE TO BE AWARDED BONUSES BASED UPON THEIR PERFORMANCE FOR THE FISCAL YEAR. THE AMOUNTS WERE $30,000, $17,500, AND $20,000, RESPECTIVELY. THE CAMDEN COUNTY IMPROVEMENT AUTHORITY 222681222 2008-07-02 6000000 FINANCE THE RENOVATION OF LABORATORY/OFFICE SPACE AND PURCHASE EQUIPMENT 0 0 0 1311439 6000000 119000 5881000 2010 0 0 1 1 0 0 0 0 0.00000 0.00000 0.00000 1 1 1 1 TD BANK 10.000000000000 0 0 0 0 0 X M CHRISTMAN PHD PURCHASE PROPERTY X 250000 201000 0 1 1 N GERRY PHD DOWN-PAYMENT ON HOUSING PURCHASE X 60000 14241 0 1 1 215241 FORM 990, PART VI, SECTION B, LINE 11 THE CHAIR OF THE AUDIT COMMITTEE REVIEWS THE FORM 990 AND PRESENTS ITS CONTENTS TO MEMBERS OF THE AUDIT AND EXECUTIVE COMMITTEES. THE FORM IS THEN DISTRIBUTED TO ALL CORIELL TRUSTEES BEFORE FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE CEO ANNUALLY DISTRIBUTES THE CONFLICT OF INTEREST POLICY AND DISCLOSURE STATEMENT TO EACH MEMBER OF THE BOARD OF TRUSTEES. EACH TRUSTEE MUST COMPLETE AND RETURN THE ANNUAL DISCLOSURE STATEMENT TO THE CEO ON A TIMELY BASIS AND INFORM THE CEO AND/OR THE COMMITTEE ON CONFLICTS OF INTEREST DIRECTLY ON A TIMELY BASIS OF ANY POTENTIAL OR ACTUAL CONFLICT OF INTEREST OR OF ANY SITUATION WHICH MIGHT LEAD TO THE APPEARANCE OF A CONFLICT OF INTEREST. IN ADDITION, THE EXECUTIVE VICE PRESIDENT ANNUALLY DISTRIBUTES A COPY OF THE EMPLOYEE CONFLICT OF INTEREST POLICY AND DISCLOSURE STATEMENT TO EACH OFFICER, EXECUTIVE, PROFESSIONAL STAFF MEMBER AND ANY INVESTIGATOR. THESE EMPLOYEES ARE REQUIRED TO SUBMIT THE COMPLETED DISCLOSURE STATEMENT TO THE EXECUTIVE VICE PRESIDENT AND DISCLOSE ANY POTENTIAL OR ACTUAL CONFLICT OF INTEREST. REPORTED CONFLICTS OF INTEREST ARE SHARED WITH THE EXECUTIVE COMMITTEE. ANY BOARD MEMBER WHO HAS A CONFLICT OF INTEREST IS EXCLUDED FROM VOTING ON ANY ISSUE INVOLVING THE CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 USING COMPARABILITY DATA SOURCED FROM AN INDEPENDENT ORGANIZATION, A BOARD OF TRUSTEES APPOINTED COMPENSATION COMMITTEE REVIEWS THE PERFORMANCE AND ESTABLISHES THE ANNUAL COMPENSATION FOR THE CHIEF EXECUTIVE OFFICER AND THE CHIEF OPERATING OFFICER. ALL COMMITTEE DISCUSSIONS ARE DOCUMENTED IN BOARD MINUTES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. CHANGES IN NET ASSETS OR FUND BALANCES: FORM 990, PART XI, LINE 5: NET UNREALIZED LOSSES ON INVESTMENTS: -396,348. CHANGE IN VALUE OF SPLIT-INTEREST AGREEMENTS 25,079. CHANGE IN VALUE OF FUTURE BUILDING OCCUPANCY -64,636. CHANGE IN FAIR VALUE OF DERIVATIVE FINANCIAL INSTRUMENT -29,393. TOTAL TO FORM 990, PART XI, LINE 5: -465,298. AUDITED FINANCIAL STATEMENTS FORM 990, PART XI, LINE 2 THE ORGANIZATION'S FINANCIAL STATEMENTS ARE AUDITED BY AN INDEPENDENT CERTIFIED PUBLIC ACCOUNTANT ON A CONSOLIDATED BASIS. AUDIT COMMITTEE FORM 990, PART XII, LINE 2C THE ORGANIZATION HAS A COMMITTEE THAT ASSUMES RESPONSIBILITY FOR OVERSEEING THE AUDIT OF ITS FINANCIAL STATEMENTS AND SELECTION OF AN INDEPENDENT CERTIFIED PUBLIC ACCOUNTANT. RELATED ORGANIZATION: FORM 990, SCHEDULE R, PARTS IV AND V THE ORGANIZATION'S RELATED ENTITY, CORIELLOGIC, HAS BEEN INACTIVE FOR YEARS AND AS SUCH THERE ARE NO ASSETS, INCOME, OR INTERCOMPANY TRANSACTIONS TO REPORT ON SCHEDULE R. REVIEW BY BOND COUNSEL FORM 990, SCHEDULE K, PART III, LINE 3C THE ORGANIZATION IS A RESEARCH FACILITY WHICH DOES NOT HAVE RENTAL AGREEMENTS OR SERVICE CONTRACTS THAT CONSTITUTE A CONTRACT WHICH MIGHT RESULT IN PRIVATE BUSINESS USE. SHOULD THE ORGANIZATION ENTER INTO AN AGREEMENT THAT WOULD NECESSITATE THE REVIEW OF BOND COUNSEL, IT WOULD DO ALL NECESSARY STEPS TO ENSURE THAT ALL SAFE HARBOR REQUIREMENTS WERE MET. CORIELLOGIC INC 403 HADDON AVENUE CAMDEN NJ 08103 222467962 COMMERCIAL DEVELOPMENT OF INSTITUTE TECHNOLOGY NJ N/A C 1.00000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 CORIELLOGIC R 4038